<DOC>
	<DOC>NCT00159861</DOC>
	<brief_summary>Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension</brief_summary>
	<brief_title>The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion PH other than PAH</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>